Neurolixis SAS awarded French 'Young Innovative Company' Status

CASTRES, France - June 4, 2015 - PRLog -- Neurolixis SAS, the French subsidiary of Neurolixis Inc., a privately held biotechnology company, announced today that it had been awarded 'Jeune Entreprise Innovante' (JEI; literally 'Young Innovative Company') status by the French Public Finances Directorate. JEI status is only awarded to recently-created companies that invest a substantial proportion of their resources into innovative research and development activities. Companies with JEI status benefit from various incentives, including tax reductions and exoneration from some social charges on employees' salaries. Neurolixis SAS' application for JEI status was vetted by the French Ministry of Research and concerns the clinical development of 2 drug candidates, NLX-112 (http://neurolixis.com/en/company/pipeline/nlx-112.html) and NLX-101 (http://neurolixis.com/en/company/pipeline/nlx-101.html). Neurolixis is developing these drugs for the treatment of dyskinesia in Parkinson's disease and for Rett syndrome (http://neurolixis.com/en/company/therapeutic-focus/rett-s...), respectively.

“We are delighted with the award of JEI status” commented Adrian Newman-Tancredi, PhD, DSc, Chief Scientific Officer, “this constitutes official recognition of Neurolixis’ commitment to innovative research and development programs.”

Obtaining JEI status will facilitate the biomedical research activities of Neurolixis SAS in France and in Europe.

About Neurolixis SAS

Neurolixis SAS, based in Castres, near Toulouse, is a privately held biotechnology company developing small molecule drugs for the treatment of neurological disorders such as Parkinson’s disease and Rett syndrome and of psychiatric disorders such as depression and schizophrenia. Additional information is available at http://www.neurolixis.com.

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.